Related Experiment Video

Updated: Apr 16, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.7K

Effect of TRPV1 gene mutation on bronchial asthma in children before and after treatment

Chuan-Liang Chen1, Hong Li, Xiao-Hong Xing

  • 1School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, Shaanxi Province, China; Henan Provincial People's Hospital, Zhengzhou, Henan Province, China.

Allergy and Asthma Proceedings
|February 26, 2015
PubMed

Insights

TRPV1 gene expression and mutations are key factors in childhood asthma. Treatment reduced inflammatory markers like IL-4, IL-5, and eosinophils, improving outcomes for pediatric asthma patients.

Area of Science:

  • Pediatric Pulmonology
  • Molecular Genetics
  • Immunology

Background:

  • Bronchial asthma is a prevalent global respiratory condition affecting children, with unclear triggers and pathogenesis.
  • Understanding the molecular mechanisms underlying pediatric asthma is crucial for effective diagnosis and treatment.

Purpose of the Study:

  • To investigate the role of Transient Receptor Potential Vanilloid 1 (TRPV1) gene mutations and cytokine expression in children with acute bronchial asthma.
  • To provide theoretical guidance for diagnosing and treating pediatric bronchial asthma.

Main Methods:

  • Real-time quantitative polymerase chain reaction (PCR) to measure TRPV1 mRNA levels.
  • Enzyme-linked immunosorbent assay (ELISA) to quantify serum total IgE, eosinophils (EOS), Interleukin-4 (IL-4), Interleukin-5 (IL-5), and Interferon-gamma (IFN-γ).
  • Logistic regression analysis to identify key risk factors for pediatric asthma.

Main Results:

  • Children with asthma exhibited higher TRPV1 mRNA levels, elevated IL-4, IL-5, and EOS, and lower IFN-γ compared to healthy controls.
  • Post-treatment, TRPV1 mRNA levels increased, while IL-4, IL-5, EOS, and IgE levels decreased significantly; IFN-γ levels increased.
  • TRPV1 expression, IL-4 levels, and rs4790522 site mutation were identified as major risk factors for pediatric bronchial asthma.

Conclusions:

  • TRPV1 gene mutations are closely associated with the development of bronchial asthma in children.
  • These findings offer a theoretical foundation for improving the treatment strategies and prognosis of pediatric asthma.

More Related Videos

In vitro Measurements of Tracheal Constriction Using Mice10:20

In vitro Measurements of Tracheal Constriction Using Mice

Published on: June 25, 2012

21.5K
Standardized Measurement of Nasal Membrane Transepithelial Potential Difference NPD09:47

Standardized Measurement of Nasal Membrane Transepithelial Potential Difference NPD

Published on: September 13, 2018

17.5K

Related Concept Videos

Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.7K
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
5.0K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.4K
Asthma-I: Introduction01:29

Asthma-I: Introduction

Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
3.8K
Asthma-III: Symptoms and Complications01:24

Asthma-III: Symptoms and Complications

Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
3.7K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
2.3K